Cristian Guja

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 16

Top Topics

Randomized Controlled Trial

Community Dwelling

Cardiovascular Risk Factors

Top Venues

Diabetes, obesity & metabolism

Endocrine research

Diabetes therapy : research, treatment and education of diabetes and related disorders

This page only lists publications with an associated author ORCID identifier.

Publications

Jochen Seufert, Nick Freemantle, Cristian Guja, Martin Haluzík, Mathilde Tournay, Carine Vera, Mireille Bonnemaire, Janos T Kis
Real-life effectiveness of iGlarLixi (insulin glargine 100 U/mL and lixisenatide) in people with type 2 diabetes according to prior insulin use. Diabetes, obesity & metabolism 26 (7) (2024)
Jochen Seufert, Nick Freemantle, Cristian Guja, Martin Haluzík, Mathilde Tournay, Carine Vera, Mireille Bonnemaire, Janos T Kis
Real-life effectiveness of iGlarLixi (insulin glargine 100 U/mL and lixisenatide) in people with type 2 diabetes according to prior insulin use. Diabetes, obesity & metabolism (2024)
Cristian Guja, János Tibor Kis, Martin Haluzík, Mireille Bonnemaire, Gregory Bigot, Mathilde Tournay, Nick Freemantle, Jochen Seufert
iGlarLixi (insulin glargine 100 U/mL plus lixisenatide) is effective and well-tolerated in people with uncontrolled type 2 diabetes regardless of age: A REALI pooled analysis of prospective real-world data. Diabetes, obesity & metabolism (2023)
Cristian Guja, János Tibor Kis, Martin Haluzík, Mireille Bonnemaire, Gregory Bigot, Mathilde Tournay, Nick Freemantle, Jochen Seufert
iGlarLixi (insulin glargine 100 U/ml plus lixisenatide) is effective and well tolerated in people with uncontrolled type 2 diabetes regardless of age: A REALI pooled analysis of prospective real-world data. Diabetes, obesity & metabolism (2023)
Cristian Guja, Francesco Giorgino, Lawrence Blonde, Amar Ali, Martin Prázný, Juris J Meier, Elisabeth Souhami, Robert Lubwama, Chen Ji, Julio Rosenstock
Concomitant iGlarLixi and Sodium-Glucose Co-transporter-2 Inhibitor Therapy in Adults with Type 2 Diabetes: LixiLan-G Trial and Real-World Evidence Results. Diabetes therapy : research, treatment and education of diabetes and related disorders (2021)
Annemarie B van der Aart-van der Beek, Daniel H van Raalte, Cristian Guja, Klaas Hoogenberg, Lisa J Suchower, Elise Hardy, C David Sjöström, Hiddo J Lambers Heerspink
Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: Pooled analysis of randomized active controlled clinical trials. Diabetes, obesity & metabolism 22 (9) (2020)
Serge A Jabbour, Juan Pablo Frias, Azazuddin Ahmed, Elise Hardy, Jasmine Choi, C David Sjöström, Cristian Guja
Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial. Diabetes care 43 (10) (2020)
Ariana Picu, Laura Petcu, Diana Simona Ştefan, Grațiela Grădișteanu Pîrcălăbioru, Manuela Mitu, Daiana Bajko, Daniela Lixandru, Cristian Guja, Octavian Savu, Anca Mihaela Pantea Stoian, Alina Constantin, Bogdan Smeu, Cătălin Copăescu, Mariana Carmen Chifiriuc, Elena Ionica, Constantin Ionescu-Tîrgovişte
Evolution of Inflammatory and Oxidative Stress Markers in Romanian Obese Male Patients with Type 2 Diabetes Mellitus after Laparoscopic Sleeve Gastrectomy: One Year Follow-Up. Metabolites 10 (8) (2020)
Francesco Rubino, Enrico Repetto, Cristian Guja, Elise Hardy, Jenny Han, Serge A Jabbour, Eleuterio Ferrannini
Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes. Diabetes, obesity & metabolism 22 (3) (2019)
Serge A Jabbour, Juan P Frías, Elise Hardy, Azazuddin Ahmed, Hui Wang, Peter Öhman, Cristian Guja
Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial. Diabetes care 41 (10) (2018)
Juan Pablo Frias, Elise Hardy, Azazuddin Ahmed, Peter Öhman, Serge A Jabbour, Hui Wang, Cristian Guja
Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION-8 randomized controlled trial. Diabetes, obesity & metabolism 20 (6) (2018)
Cristian Guja, Juan Pablo Frias, Aniko Somogyi, Serge A Jabbour, Hui Wang, Elise Hardy, Julio Rosenstock
Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study. Diabetes, obesity & metabolism 20 (7) (2018)
Sorin Ioacara, Cristian Guja, Aura Reghina, Sorina Carmen Martin, Anca Elena Sirbu, Simona Fica
All-cause and cardiovascular mortality associated with sulphonylurea and metformin therapy in type 2 diabetes. Endocrine research 43 (2) (2018)
Sorin Ioacara, Cristian Guja, Constantin Ionescu-Tîrgoviște, Sorina Carmen Martin, Cristina Tiu, Simona Fica
Rates and Causes of Death among Adult Diabetes Patients in Romania. Endocrine research 44 (3) (2018)
Serge A Jabbour, Juan Pablo Frias, Cristian Guja, Elise Hardy, Azazuddin Ahmed, Peter Öhman
Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study. Diabetes, obesity & metabolism 20 (6) (2018)
Stephen C Bain, Ofri Mosenzon, Rosario Arechavaleta, Pawel Bogdański, Abdurrahman Comlekci, Agostino Consoli, Chaicharn Deerochanawong, Kathleen M Dungan, Maria C Faingold, Michael E Farkouh, Denise R Franco, Jeppe Gram, Cristian Guja, Pankaj Joshi, Rachid Malek, Juan F Merino-Torres, Michael A Nauck, Sue D Pedersen, Wayne H-H Sheu, Robert J Silver, Cees J Tack, Nikhil Tandon, Ole K Jeppesen, Mette Strange, Mette Thomsen, Mansoor Husain
Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial. Diabetes, obesity & metabolism 21 (3) (2018)